Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD; DISCOVER study team. Ogbuagu O, et al. Among authors: podzamczer d. Lancet HIV. 2021 Jul;8(7):e397-e407. doi: 10.1016/S2352-3018(21)00071-0. Lancet HIV. 2021. PMID: 34197772 Clinical Trial.
Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV.
Rigo-Bonnin R, García-Tejada L, Mas-Bosch V, Imaz A, Manuel Tiraboschi J, Scévola S, Niubó J, Navarro-Alcaraz A, Podzamczer D. Rigo-Bonnin R, et al. Among authors: podzamczer d. Clin Chim Acta. 2024 Jan 1;552:117678. doi: 10.1016/j.cca.2023.117678. Epub 2023 Nov 30. Clin Chim Acta. 2024. PMID: 38042460
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, Hernández C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadellà M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A. Podzamczer D, et al. J Antimicrob Chemother. 2023 Nov 6;78(11):2696-2701. doi: 10.1093/jac/dkad285. J Antimicrob Chemother. 2023. PMID: 37725999 Clinical Trial.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
Scévola S, Niubó J, Domingo P, Verdejo G, Curran A, Diaz-Brito V, Peñafiel J, Tiraboschi J, Morenilla S, Garcia B, Soriano I, Podzamczer D, Imaz A. Scévola S, et al. Among authors: podzamczer d. J Infect Dis. 2023 Oct 3;228(7):919-925. doi: 10.1093/infdis/jiad304. J Infect Dis. 2023. PMID: 37526315 Clinical Trial.
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
Santos JR, Casadellà M, Noguera-Julian M, Micán-Rivera R, Domingo P, Antela A, Portilla J, Sanz J, Montero-Alonso M, Navarro J, Masiá M, Valcarce-Pardeiro N, Ocampo A, Pérez-Martínez L, García-Vallecillos C, Vivancos MJ, Imaz A, Iribarren JA, Hernández-Quero J, Villar-García J, Barrufet P, Paredes R; INSTINCT study group. Santos JR, et al. Front Cell Infect Microbiol. 2023 Jun 26;13:1187999. doi: 10.3389/fcimb.2023.1187999. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37434782 Free PMC article.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV.
Donadeu L, Tiraboschi JM, Scévola S, Torija A, Meneghini M, Jouve T, Favà A, Calatayud L, Ardanuy C, Cidraque I, Preyer R, Strecker K, Lozano JJ, Podzamczer D, Crespo E, Bestard O. Donadeu L, et al. Among authors: podzamczer d. AIDS. 2022 Aug 1;36(10):1373-1382. doi: 10.1097/QAD.0000000000003276. Epub 2022 Jun 22. AIDS. 2022. PMID: 35730384
363 results